Skip Nav Destination
Progress in Respiratory Research
New Drugs for Asthma, Allergy and COPD
Edited by
S.Karger AG
Volume
31
Status:
Out of Print Available Online
ISBN electronic:
978-3-318-00424-3
ISBN print:
978-3-8055-6862-3
Book Series:
Progress in Respiratory Research
Publication date:
2001
Book Details
This book provides a state-of-the-art account by academic respiratory physicians and senior pharmaceutical industry personnel on the development of new drugs for asthma, allergy and COPD. It contains 80 chapters of highly condensed information, presented in an attractive, reader-friendly format with much use of tables, figures and diagrams. In addition to summarizing the diverse range of current approaches, this handbook also looks into the future, considering many topics that are promising, but have only emerged in the last few years. Developments within established drug categories such as beta-2-agonists, steroids and leukotriene antagonists are also reviewed. Never before has a single book brought together so many pharmaceutical drug developers sharing their experience on such a wide range of respiratory topics!
New Drugs for Asthma, Allergy and COPD
Edited by: T.T. Hansel, P.J. Barnes
https://doi.org/10.1159/isbn.978-3-318-00424-3
ISBN (print): 978-3-8055-6862-3
ISBN (electronic): 978-3-318-00424-3
Publisher: S.Karger AG
Published: 2001
Download citation file:
Digital Version
Pay-Per-View Access
$332.00
Table of Contents
-
2 - 5: The Need for New TherapyByPeter J. Barnes;Peter J. BarnesDepartment of Thoracic Medicine, National Heart and Lung Institute, Imperial College, London, UKSearch for other works by this author on:Trevor T. HanselTrevor T. HanselDepartment of Thoracic Medicine, National Heart and Lung Institute, Imperial College, London, UKSearch for other works by this author on:
-
6 - 10: Current Therapy for AsthmaByPeter J. BarnesPeter J. BarnesDepartment of Thoracic Medicine, National Heart and Lung Institute, Imperial College, London, UKSearch for other works by this author on:
-
11 - 14: Current Therapy for COPDByRomain PauwelsRomain PauwelsDepartment of Respiratory Diseases, Ghent University Hospital, Ghent, BelgiumSearch for other works by this author on:
-
15 - 19: PharmacogeneticsByIan P. Hall;Ian P. HallaDivision of Therapeutics, University Hospital, Nottingham, andSearch for other works by this author on:Trevor T. HanselTrevor T. HanselbNational Heart and Lung Institute, Clinical Studies Unit, Imperial College, London, UKSearch for other works by this author on:
-
20 - 23: Delivery of Biologics to the LungByDavid Cipolla;David CipollaAradigm Corporation, Hayward, Calif., USASearch for other works by this author on:Stephen Farr;Stephen FarrAradigm Corporation, Hayward, Calif., USASearch for other works by this author on:Igor Gonda;Igor GondaAradigm Corporation, Hayward, Calif., USASearch for other works by this author on:Babatunde OtulanaBabatunde OtulanaAradigm Corporation, Hayward, Calif., USASearch for other works by this author on:
-
24 - 29: Immunopathology: Comparison of COPD and AsthmaByPeter K. JefferyPeter K. JefferyImperial College School of Medicine at the National Heart and Lung Institute, London, UKSearch for other works by this author on:
-
30 - 34: Monitoring Lung FunctionByNeil PrideNeil PrideDepartment of Thoracic Medicine, National Heart and Lung Institute, Imperial College School of Medicine, London, UKSearch for other works by this author on:
-
35 - 38: Airway HyperresponsivenessByPeter J. SterkPeter J. SterkLung Function Laboratory, Department of Pulmonology, Leiden University Medical Centre, Leiden, The NetherlandsSearch for other works by this author on:
-
39 - 43: Airways RemodellingByStephen T. Holgate;Stephen T. HolgateRCMB Research Division, School of Medicine, University of Southampton, Southampton General Hospital, Southampton, UKSearch for other works by this author on:Donna E. DaviesDonna E. DaviesRCMB Research Division, School of Medicine, University of Southampton, Southampton General Hospital, Southampton, UKSearch for other works by this author on:
-
44 - 47: Exhaled Breath AnalysisBySergei A. Kharitonov;Sergei A. KharitonovDepartment of Thoracic Medicine, National Heart and Lung Institute, Imperial College School of Medicine, London, UKSearch for other works by this author on:Peter J. BarnesPeter J. BarnesDepartment of Thoracic Medicine, National Heart and Lung Institute, Imperial College School of Medicine, London, UKSearch for other works by this author on:
-
48 - 51: Clinical Studies on New DrugsByTrevor T. Hansel;Trevor T. HanselaNational Heart and Lung Institute (NHLI) Clinical Studies Unit andSearch for other works by this author on:Peter J. BarnesPeter J. BarnesbDepartment of Thoracic Medicine, NHLI, Imperial College, London, UKSearch for other works by this author on:
-
54 - 59: Bronchodilators: An OverviewByGary P. Anderson;Gary P. AndersonaDepartment of Pharmacology, University of Melbourne, Australia, andSearch for other works by this author on:Klaus F. RabeKlaus F. RabebPulmonology, Leiden University Center, Leiden, The NetherlandsSearch for other works by this author on:
-
60 - 63: Long-Acting β2-AgonistsByMalcolm Johnson;Malcolm JohnsonGlaxoWellcome, Uxbridge, UKSearch for other works by this author on:Gerry W.E. HaganGerry W.E. HaganGlaxoWellcome, Uxbridge, UKSearch for other works by this author on:
-
64 - 67: Single-Isomer β-AgonistsByD.A. Handley;D.A. HandleyaSepracor, Marlborough, Mass., USA,Search for other works by this author on:J. Morley;J. MorleybHaldane Research Ltd, Huntingdon, UK, andSearch for other works by this author on:H.S. NelsonH.S. NelsoncNational Jewish Medical and Research Center, Denver, Colo., USASearch for other works by this author on:
-
68 - 71: Dual D2 Dopamine Receptor and β2-Adrenoceptor Agonists for the Modulation of Sensory Nerves in COPDByPaul Newbold;Paul NewboldAstraZeneca R & D Charnwood, Loughborough, UKSearch for other works by this author on:Dale M. Jackson;Dale M. JacksonAstraZeneca R & D Charnwood, Loughborough, UKSearch for other works by this author on:Alan Young;Alan YoungAstraZeneca R & D Charnwood, Loughborough, UKSearch for other works by this author on:Iain G. Dougall;Iain G. DougallAstraZeneca R & D Charnwood, Loughborough, UKSearch for other works by this author on:Frank Ince;Frank InceAstraZeneca R & D Charnwood, Loughborough, UKSearch for other works by this author on:Karen M.S. Rocchiccioli;Karen M.S. RocchiccioliAstraZeneca R & D Charnwood, Loughborough, UKSearch for other works by this author on:Phil R. HoltPhil R. HoltAstraZeneca R & D Charnwood, Loughborough, UKSearch for other works by this author on:
-
72 - 76: Anticholinergics: TiotropiumByBernd Disse;Bernd DisseaBoehringer Ingelheim Clinical Research Institute, Ingelheim/Rhein, Germany, andSearch for other works by this author on:Theodore J. Witek Jr.Theodore J. Witek Jr.bBoehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Conn., USASearch for other works by this author on:
-
77 - 80: Potassium Channel Openers: Agents for the Treatment of Airway HyperreactivityByJohn R. Fozard;John R. FozardPreclinical Research, Novartis Pharma Ltd., Basel, SwitzerlandSearch for other works by this author on:Paul W. ManleyPaul W. ManleyPreclinical Research, Novartis Pharma Ltd., Basel, SwitzerlandSearch for other works by this author on:
-
81 - 84: UrodilatinByKristin Forssmann;Kristin ForssmannaCardioPep Pharma GmbH andSearch for other works by this author on:Markus Meyer;Markus MeyeraCardioPep Pharma GmbH andbIPF PharmaCeuticals GmbH, Hannover, GermanySearch for other works by this author on:Wolf Georg ForsmannWolf Georg ForsmannbIPF PharmaCeuticals GmbH, Hannover, GermanySearch for other works by this author on:
-
86 - 90: Steroids: An OverviewByRonald Dahl;Ronald DahlaDepartment of Respiratory Diseases, Aarhus University Hospital, andSearch for other works by this author on:Lars Peter NielsenLars Peter NielsenbDepartment of Clinical Pharmacology, University of Aarhus, Aarhus, DenmarkSearch for other works by this author on:
-
91 - 93: Ciclesonide: An On-Site-Activated SteroidByK. Dietzel;K. DietzelByk Gulden Pharmaceuticals, Konstanz, GermanySearch for other works by this author on:R. Engelstätter;R. EngelstätterByk Gulden Pharmaceuticals, Konstanz, GermanySearch for other works by this author on:A. KellerA. KellerByk Gulden Pharmaceuticals, Konstanz, GermanySearch for other works by this author on:
-
94 - 97: Soft SteroidsByBengt Axelsson;Bengt AxelssonAstraZeneca R&D Lund, Lund, SwedenSearch for other works by this author on:Ralph BrattsandRalph BrattsandAstraZeneca R&D Lund, Lund, SwedenSearch for other works by this author on:
-
98 - 101: Dissociated SteroidsByThomas J. Brown;Thomas J. BrownAventis Pharmaceuticals, Dagenham, UKSearch for other works by this author on:Maria G. Belvisi;Maria G. BelvisiAventis Pharmaceuticals, Dagenham, UKSearch for other works by this author on:Martyn L. FosterMartyn L. FosterAventis Pharmaceuticals, Dagenham, UKSearch for other works by this author on:
-
102 - 105: Oestradiol Metabolites: Effects on Airway RemodellingByA.G. Stewart;A.G. StewartDepartment of Pharmacology, University of Melbourne, AustraliaSearch for other works by this author on:R. Vlahos;R. VlahosDepartment of Pharmacology, University of Melbourne, AustraliaSearch for other works by this author on:D.J. Fernandes;D.J. FernandesDepartment of Pharmacology, University of Melbourne, AustraliaSearch for other works by this author on:R.A. HughesR.A. HughesDepartment of Pharmacology, University of Melbourne, AustraliaSearch for other works by this author on:
-
108 - 110: Leukotriene Inhibitors: An OverviewByPaul M. O´Byrne;Paul M. O´Byrnea Asthma Research Group, St. Joseph’s Hospital and McMaster University, Hamilton, Canada, andSearch for other works by this author on:Jeffrey M. DrazenJeffrey M. DrazenbRespiratory Division, Brigham and Women’s Hospital and Harvard Medical School, Boston, Mass., USASearch for other works by this author on:
-
111 - 114: Cysteinyl Leukotriene AntagonistsByRodger M. McMillanRodger M. McMillanRespiratory and Inflammation Research Area, AstraZeneca, Macclesfield, UKSearch for other works by this author on:
-
115 - 120: 5-Lipoxygenase InhibitorsBySven-Erik DahlénSven-Erik DahlénUnit for Experimental Asthma and Allergy Research, The National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, SwedenSearch for other works by this author on:
-
121 - 125: LTB4 AntagonismByH.M. Jennewein;H.M. JenneweinBoehringer Ingelheim KG, Department of Pulmonary Research, Ingelheim, GermanySearch for other works by this author on:R. Anderskewitz;R. AnderskewitzBoehringer Ingelheim KG, Department of Pulmonary Research, Ingelheim, GermanySearch for other works by this author on:C.J. Meade;C.J. MeadeBoehringer Ingelheim KG, Department of Pulmonary Research, Ingelheim, GermanySearch for other works by this author on:M. Pairet;M. PairetBoehringer Ingelheim KG, Department of Pulmonary Research, Ingelheim, GermanySearch for other works by this author on:F. BirkeF. BirkeBoehringer Ingelheim KG, Department of Pulmonary Research, Ingelheim, GermanySearch for other works by this author on:
-
128 - 132: H1-AntihistaminesByJ.P. RihouxJ.P. RihouxUCB Pharma SA, Brussels, BelgiumSearch for other works by this author on:
-
133 - 136: Histamine H3 AntagonistsByRobbie L. McLeod;Robbie L. McLeodaAllergy, Schering-Plough Research Institute, Kenilworth, N.J., andSearch for other works by this author on:Robert W. Egan;Robert W. EganaAllergy, Schering-Plough Research Institute, Kenilworth, N.J., andSearch for other works by this author on:Francis M. Cuss;Francis M. CussaAllergy, Schering-Plough Research Institute, Kenilworth, N.J., andSearch for other works by this author on:Donald C. Bolser;Donald C. BolserbDepartment of Physiological Sciences, University of Gainesville, Fla., USASearch for other works by this author on:John A. HeyJohn A. HeyaAllergy, Schering-Plough Research Institute, Kenilworth, N.J., andSearch for other works by this author on:
-
137 - 140: Kinin Receptor AntagonistsByStefania Meini;Stefania MeiniPharmacology Department, Menarini Ricerche SpA, Florence, ItalySearch for other works by this author on:Carlo Alberto MaggiCarlo Alberto MaggiPharmacology Department, Menarini Ricerche SpA, Florence, ItalySearch for other works by this author on:
-
141 - 144: Endothelin AntagonistsByDouglas W.P. Hay;Douglas W.P. HayaDepartment of Pulmonary Biology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pa., USA, andSearch for other works by this author on:Christopher H. ComptonChristopher H. ComptonbDepartment of Clinical Investigation, SmithKline Beecham Pharmaceuticals, Harlow, UKSearch for other works by this author on:
-
145 - 150: Tachykinin AntagonistsByDouglas W.P. HayDouglas W.P. HayDepartment of Pulmonary Biology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pa., USASearch for other works by this author on:
-
151 - 155: AntioxidantsByWilliam MacNeeWilliam MacNeeELEGI Colt Research Laboratories, University of Edinburgh Medical School, Edinburgh, UKSearch for other works by this author on:
-
156 - 159: Selective iNOS InhibitorsByPamela T. Manning;Pamela T. ManningaSearle Research and Development, St. Louis, Mo., andSearch for other works by this author on:Mark G. CurrieMark G. CurriecSepracor Inc., Marlborough, Mass., USASearch for other works by this author on:
-
160 - 164: Mucus RegulationByDuncan F. RogersDuncan F. RogersThoracic Medicine, National Heart and Lung Institute, Imperial College, London, UKSearch for other works by this author on:
-
165 - 168: P2Y Receptor Agonists: Role in Mucosal Hydration and Mucociliary ClearanceByWilliam Pendergast;William PendergastInspire Pharmaceuticals, Inc., Durham, N.C., USASearch for other works by this author on:Richard EvansRichard EvansInspire Pharmaceuticals, Inc., Durham, N.C., USASearch for other works by this author on:
-
170 - 172: Tryptase InhibitionByJames M. Clark;James M. ClarkAxys Pharmaceuticals, Inc., South San Francisco, Calif., USASearch for other works by this author on:Robert E. van Dyke;Robert E. van DykeAxys Pharmaceuticals, Inc., South San Francisco, Calif., USASearch for other works by this author on:Matthias C. KurthMatthias C. KurthAxys Pharmaceuticals, Inc., South San Francisco, Calif., USASearch for other works by this author on:
-
173 - 176: Neutrophil Elastase InhibitorsByRobin A. Smith;Robin A. SmithaGlaxoWellcome R&D, Stevenage, andSearch for other works by this author on:Robert A. Stockley;Robert A. StockleybDepartment of Medicine, Queen Elizabeth Hospital, Birmingham, UKSearch for other works by this author on:Simon T. HodgsonSimon T. HodgsonaGlaxoWellcome R&D, Stevenage, andSearch for other works by this author on:
-
177 - 180: Macrophage Metalloelastase InhibitorsByRobert L. Martin;Robert L. MartinaInflammatory Diseases Unit, Roche Bioscience, Palo Alto, Calif., andSearch for other works by this author on:Steven D. Shapiro;Steven D. ShapirobDepartment of Medicine, Washington University, St. Louis, Mo., USASearch for other works by this author on:Sandra E. Tong;Sandra E. TongaInflammatory Diseases Unit, Roche Bioscience, Palo Alto, Calif., andSearch for other works by this author on:Harold E. van WartHarold E. van WartaInflammatory Diseases Unit, Roche Bioscience, Palo Alto, Calif., andSearch for other works by this author on:
-
181 - 185: Allergen, IgE and Mast-Cell-Directed Therapies: An OverviewByMark Larché;Mark LarchéDepartment of Allergy and Clinical Immunology, Imperial College School of Medicine, National Heart and Lung Institute, London, UKSearch for other works by this author on:A. Barry KayA. Barry KayDepartment of Allergy and Clinical Immunology, Imperial College School of Medicine, National Heart and Lung Institute, London, UKSearch for other works by this author on:
-
186 - 190: Allergen ImmunotherapyByDuncan R. Wilson;Duncan R. WilsonUpper Respiratory Medicine, Imperial College School of Medicine, National Heart and Lung Institute, London, UKSearch for other works by this author on:Stephen R. DurhamStephen R. DurhamUpper Respiratory Medicine, Imperial College School of Medicine, National Heart and Lung Institute, London, UKSearch for other works by this author on:
-
191 - 194: Peptide ImmunotherapyByWilliam L.G. Oldfield;William L.G. OldfieldDepartment of Allergy and Clinical Immunology, Imperial College School of Medicine, National Heart and Lung Institute, London, UKSearch for other works by this author on:A. Barry Kay;A. Barry KayDepartment of Allergy and Clinical Immunology, Imperial College School of Medicine, National Heart and Lung Institute, London, UKSearch for other works by this author on:Mark LarchéMark LarchéDepartment of Allergy and Clinical Immunology, Imperial College School of Medicine, National Heart and Lung Institute, London, UKSearch for other works by this author on:
-
195 - 200: Recombinant AllergensByRudolf Valenta;Rudolf ValentaDepartment of Pathophysiology, University of Vienna, AustriaSearch for other works by this author on:Dietrich KraftDietrich KraftDepartment of Pathophysiology, University of Vienna, AustriaSearch for other works by this author on:
-
201 - 205: Anti-IgE AntibodyByHomer A. Boushey;Homer A. BousheyaDepartment of Medicine, University of California, San Francisco, Calif., andSearch for other works by this author on:Robert Fick;Robert FickbGenentech, Inc., S. San Francisco, Calif., USASearch for other works by this author on:John V. FahyJohn V. FahyaDepartment of Medicine, University of California, San Francisco, Calif., andSearch for other works by this author on:
-
206 - 209: CD23ByDaniel H. ConradDaniel H. ConradVirginia Commonwealth University, Richmond, Va., USASearch for other works by this author on:
-
212 - 216: T Cell Immunomodulation: An OverviewByAthanasios Koulis;Athanasios KoulisAllergy and Clinical Immunology, Imperial College School of Medicine, National Heart and Lung Institute, London, UKSearch for other works by this author on:Douglas S. RobinsonDouglas S. RobinsonAllergy and Clinical Immunology, Imperial College School of Medicine, National Heart and Lung Institute, London, UKSearch for other works by this author on:
-
217 - 221: Costimulatory Molecules in T Cell ActivationByAnthony J. Coyle;Anthony J. CoyleMillennium Pharmaceuticals Inc., Cambridge, Mass., USASearch for other works by this author on:Jose-Carlos Gutierrez-RamosJose-Carlos Gutierrez-RamosMillennium Pharmaceuticals Inc., Cambridge, Mass., USASearch for other works by this author on:
-
222 - 225: GATA-3: A Th2-Selective TargetByAnuradha Ray;Anuradha RayDepartment of Medicine, Pulmonary and Critical Care Section, Yale University School of Medicine, New Haven, Conn., USASearch for other works by this author on:Prabir RayPrabir RayDepartment of Medicine, Pulmonary and Critical Care Section, Yale University School of Medicine, New Haven, Conn., USASearch for other works by this author on:
-
226 - 228: Mycobacterial Immunization: Agents to Limit AsthmaByJulian M. HopkinJulian M. HopkinExperimental Medicine Unit, University of Wales, Swansea, UKSearch for other works by this author on:
-
229 - 232: CpG OligodeoxynucleotidesByArthur M. KriegArthur M. KriegaUniversity of Iowa,bVeterans Affairs Medical Center, Iowa City, Iowa, andcColey Pharmaceutical Group, Wellesley, Mass., USASearch for other works by this author on:
-
233 - 236: CD8 T Cells: Potential Therapeutic Targets?ByTheo A. Out;Theo A. OutaClinical Immunology Laboratory andcCLB Sanquin Blood Supply Foundation, Amsterdam, The Netherlands, andSearch for other works by this author on:Francina L. de Pater-Huijsen;Francina L. de Pater-HuijsenaClinical Immunology Laboratory andbDepartment of Pulmonology, Academic Medical Center, Amsterdam andSearch for other works by this author on:Henk M. Jansen;Henk M. JansenbDepartment of Pulmonology, Academic Medical Center, Amsterdam andSearch for other works by this author on:Chris J. CorriganChris J. CorrigandDepartment of Respiratory Medicine and Allergy, Guy’s, King’s and St. Thomas’ School of Medicine, London, UKSearch for other works by this author on:
-
237 - 240: Macrocyclic ImmunosuppressantsByThomas H. Keller;Thomas H. KelleraNovartis Horsham Research Center, Horsham, UK, andSearch for other works by this author on:René Hersperger;René HerspergerbNovartis Pharma, Basel, SwitzerlandSearch for other works by this author on:Giovanni Della CioppaGiovanni Della CioppaaNovartis Horsham Research Center, Horsham, UK, andSearch for other works by this author on:
-
242 - 246: Cytokines: An OverviewByK. Fan ChungK. Fan ChungNational Heart and Lung Institute, Imperial College School of Medicine, London, UKSearch for other works by this author on:
-
247 - 250: TNF AntagonismByNeil D. McDonnell;Neil D. McDonnellaImmunex Corporation, Seattle, Wash., USA,Search for other works by this author on:Nicholas N. Abbott;Nicholas N. AbbottaImmunex Corporation, Seattle, Wash., USA,Search for other works by this author on:Kendall M. Mohler;Kendall M. MohleraImmunex Corporation, Seattle, Wash., USA,Search for other works by this author on:Trevor T. Hansel;Trevor T. HanselbNHLI Clinical Studies Unit, Imperial College, London, UK, andSearch for other works by this author on:Johan C. KipsJohan C. KipscDepartment of Respiratory Diseases, Ghent University Hospital, Ghent, BelgiumSearch for other works by this author on:
-
251 - 255: GM-CSF AntagonistsByWilliam V. WilliamsWilliam V. WilliamsClinical Pharmacology, SmithKline Beecham, Philadelphia, Pa., USASearch for other works by this author on:
-
256 - 259: Interleukin-4 AntagonismByLarry Borish;Larry BorishaUniversity of Virginia, Charlottesville, Va., andSearch for other works by this author on:Jan M. AgostiJan M. AgostibImmunex Corporation, Seattle, Wash., USASearch for other works by this author on:
-
260 - 264: Interleukin-13 AntagonismByDebra D. Donaldson;Debra D. DonaldsonaGenetics Institute of Wyeth-Ayerst Research, Andover, Mass.;Search for other works by this author on:Jack A. Elias;Jack A. EliasbYale University, New Haven, Conn.;Search for other works by this author on:Marsha Wills-KarpMarsha Wills-KarpcJohns Hopkins University, Baltimore, Md., USASearch for other works by this author on:
-
265 - 268: Interleukin-5 AntagonismByMaggie J. Leckie;Maggie J. LeckieaNational Heart and Lung Institute, Clinical Studies Unit, Imperial College, London, andSearch for other works by this author on:Christoph WalkerChristoph WalkerbNovartis Research Centre, Horsham, UKSearch for other works by this author on:
-
269 - 273: Interleukin-10BySatwant Narula;Satwant NarulaDepartment of Immunology and Allergy Drug Discovery, Schering-Plough Research Institute, Kenilworth, N.J., USASearch for other works by this author on:Francis CussFrancis CussDepartment of Immunology and Allergy Drug Discovery, Schering-Plough Research Institute, Kenilworth, N.J., USASearch for other works by this author on:
-
274 - 278: Interleukin-12, Interleukin-18 and Interferon-γByShannon Bryan;Shannon BryanaNational Heart and Lung Institute, Clinical Studies Unit, Imperial College, London, UK;Search for other works by this author on:Michiko Kobayashi;Michiko KobayashibImmunology and Hemostasis, Genetics Institute of Wyeth-Ayerst Research, Andover, Mass., USA, andSearch for other works by this author on:Sanjiv SurSanjiv SurcDepartment of Internal Medicine, Division of Allergy and Immunology, NIAID Asthma Center,University of Texas Medical Branch, Galveston, Tex., USASearch for other works by this author on:
-
280 - 283: Chemokines: An OverviewByIan Sabroe;Ian SabroeImperial College, Division of Biomedical Sciences, South Kensington, UKSearch for other works by this author on:Timothy J. WilliamsTimothy J. WilliamsImperial College, Division of Biomedical Sciences, South Kensington, UKSearch for other works by this author on:
-
284 - 287: Chemokine Receptors on Th1 and Th2 CellsByFrancesco Sinigaglia;Francesco SinigagliaaRoche Milano Ricerche, Milan,Search for other works by this author on:Leonardo M. Fabbri;Leonardo M. FabbribSection of Respiratory Diseases, University of Modena, Modena, ItalySearch for other works by this author on:Daniele D´AmbrosioDaniele D´AmbrosioaRoche Milano Ricerche, Milan,Search for other works by this author on:
-
288 - 292: CCR-3 AntagonistsByShannon A. Bryan;Shannon A. BryanaNational Heart and Lung Institute, Clinical Studies Unit, Imperial College, London, UK,Search for other works by this author on:Paul D. Ponath;Paul D. PonathbLeukoSite, Inc., Cambridge, Mass., and Boston, Mass.,Search for other works by this author on:Robert S. WilhelmRobert S. WilhelmcInflammatory Diseases Unit, Roche Bioscience, Palo Alto, Calif., USASearch for other works by this author on:
-
293 - 296: Interleukin-8 Receptor (CXCR2) AntagonistsByHenry M. Sarau;Henry M. SarauDepartments of Pulmonary Biology, Medicinal Chemistry and Immunology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pa., USASearch for other works by this author on:Katherine L. Widdowson;Katherine L. WiddowsonDepartments of Pulmonary Biology, Medicinal Chemistry and Immunology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pa., USASearch for other works by this author on:Michael R. Palovich;Michael R. PalovichDepartments of Pulmonary Biology, Medicinal Chemistry and Immunology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pa., USASearch for other works by this author on:John R. White;John R. WhiteDepartments of Pulmonary Biology, Medicinal Chemistry and Immunology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pa., USASearch for other works by this author on:David C. Underwood/surname;David C. Underwood/surnameDepartments of Pulmonary Biology, Medicinal Chemistry and Immunology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pa., USASearch for other works by this author on:Don E. GriswoldDon E. GriswoldDepartments of Pulmonary Biology, Medicinal Chemistry and Immunology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pa., USASearch for other works by this author on:
-
298 - 301: Adhesion Molecule Antagonism: An OverviewByBruce S. BochnerBruce S. BochnerDepartment of Medicine, Division of Clinical Immunology, The Johns Hopkins University School of Medicine, Johns Hopkins Asthma and Allergy Center, Baltimore, Md., USASearch for other works by this author on:
-
302 - 305: Small-Molecule VLA-4 AntagonistsBySteven P. Adams;Steven P. AdamsBiogen Inc., Cambridge Mass., USASearch for other works by this author on:Roy R. LobbRoy R. LobbBiogen Inc., Cambridge Mass., USASearch for other works by this author on:
-
306 - 309: Selectin Antagonists: Therapeutics for Airway InflammationByKurt L. Berens;Kurt L. BerensTexas Biotechnology Corporation, Houston, Tex., USASearch for other works by this author on:Peter Vanderslice;Peter VandersliceTexas Biotechnology Corporation, Houston, Tex., USASearch for other works by this author on:Brian Dupré;Brian DupréTexas Biotechnology Corporation, Houston, Tex., USASearch for other works by this author on:Richard A.F. DixonRichard A.F. DixonTexas Biotechnology Corporation, Houston, Tex., USASearch for other works by this author on:
-
310 - 313: ICAM-1 and VCAM-1 AntagonistsByIvan M. Richards;Ivan M. RichardsPharmacia Corporation, Kalamazoo, Mich., USASearch for other works by this author on:Vandana Khare SlatterVandana Khare SlatterPharmacia Corporation, Kalamazoo, Mich., USASearch for other works by this author on:
-
316 - 320: Eosinophil G-Protein-Coupled Receptor Signalling: An OverviewByMark A. Lindsay;Mark A. LindsayThoracic Medicine, National Heart and Lung Institute, Imperial College School of Medicine, London, UKSearch for other works by this author on:Patricia M. De Souzar;Patricia M. De SouzarThoracic Medicine, National Heart and Lung Institute, Imperial College School of Medicine, London, UKSearch for other works by this author on:Oonagh T. Lynch;Oonagh T. LynchThoracic Medicine, National Heart and Lung Institute, Imperial College School of Medicine, London, UKSearch for other works by this author on:Mark A. GiembyczMark A. GiembyczThoracic Medicine, National Heart and Lung Institute, Imperial College School of Medicine, London, UKSearch for other works by this author on:
-
321 - 325: Phosphodiesterase 4 InhibitorsByTheodore J. Torphy;Theodore J. TorphyaSmithKline Beecham Pharmaceuticals, King of Prussia, Pa., USA,Search for other works by this author on:Christopher H. Compton;Christopher H. ComptonbHarlow, UK, andSearch for other works by this author on:Meretta J. Marks;Meretta J. MarkscCollegeville, Pa., USA, andSearch for other works by this author on:Graham SturtonGraham SturtondBayer plc Pharma Research, Stoke Poges, Slough, UKSearch for other works by this author on:
-
328 - 331: Therapies Acting on Transcription: An OverviewByG. Caramori;G. CaramoriThoracic Medicine, National Heart and Lung Institute, Imperial College of Science, Technology and Medicine, London, UKSearch for other works by this author on:I.M. AdcockI.M. AdcockThoracic Medicine, National Heart and Lung Institute, Imperial College of Science, Technology and Medicine, London, UKSearch for other works by this author on:
-
332 - 336: Chromatin ModificationByFyodor D. Urnov;Fyodor D. UrnovSangamo Biosciences, Richmond, Calif., USASearch for other works by this author on:Alan P. WolffeAlan P. WolffeSangamo Biosciences, Richmond, Calif., USASearch for other works by this author on:
-
337 - 341: Activator Protein-1 and Nuclear Factor-Kappa BByBrydon L. Bennett;Brydon L. BennettSignal Pharmaceuticals, Inc., San Diego, Calif., USASearch for other works by this author on:Anthony M. ManningAnthony M. ManningSignal Pharmaceuticals, Inc., San Diego, Calif., USASearch for other works by this author on:
-
342 - 345: Inhibition of p38 MAP KinaseByDavid C. Underwood;David C. UnderwoodDepartment of Pulmonary Biology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pa., USASearch for other works by this author on:Don E. GriswoldDon E. GriswoldDepartment of Pulmonary Biology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pa., USASearch for other works by this author on:
-
346 - 349: STAT6: Role in IL-4-Mediated SignalingByGabriele Schaefer;Gabriele SchaeferTularik, Inc., South San Francisco, Calif., USASearch for other works by this author on:Chandrasekar Venkataraman;Chandrasekar VenkataramanTularik, Inc., South San Francisco, Calif., USASearch for other works by this author on:Ulrike SchindlerUlrike SchindlerTularik, Inc., South San Francisco, Calif., USASearch for other works by this author on:
-
350 - 355: RetinoidsByPaula N. BelloniPaula N. BelloniRoche Bioscience, Palo Alto, Calif., USASearch for other works by this author on:
-
358 - 360: Asthma and COPD Genetics and Genomics: An OverviewByJohn F.J. MorrisonJohn F.J. MorrisonGlobal Clinical Genomics, AstraZeneca R&D, Macclesfield, UKSearch for other works by this author on:
-
361 - 364: Respirable Antisense OligonucleotidesByJonathan W. NyceJonathan W. NyceEpiGenesis Pharmaceuticals, Inc., Princeton, N.J., USASearch for other works by this author on:
-
365 - 369: Antisense TherapyByC.Frank BennettC.Frank BennettIsis Pharmaceuticals, Inc., Carlsbad, Calif., USASearch for other works by this author on:
-
370 - 373: Ribozyme TherapyByJennifer A. Sandberg;Jennifer A. SandbergRibozyme Pharmaceuticals, Inc., Boulder, Colo., USASearch for other works by this author on:Patrice A. Lee;Patrice A. LeeRibozyme Pharmaceuticals, Inc., Boulder, Colo., USASearch for other works by this author on:Nassim UsmanNassim UsmanRibozyme Pharmaceuticals, Inc., Boulder, Colo., USASearch for other works by this author on:
-
374 - 378: Gene TherapyByMartin Kolb;Martin KolbDepartment of Pathology, McMaster University, Hamilton, CanadaSearch for other works by this author on:Jack GauldieJack GauldieDepartment of Pathology, McMaster University, Hamilton, CanadaSearch for other works by this author on:
